- Trial phase
- Phase 1b/2a (completed)
- Time to market
- Unknown; no Phase 2b or pivotal trial has been announced. If a Phase 2b/3 program were started in 2027, potential approval would be several years away (likely 2029-2031 at the earliest).
- Why 3/10
- No hard dated catalyst is scheduled for VK0214 in the next ~12 months. The Phase 1b/2a trial is complete with no announced next-phase start. VK0214 is a minor program dwarfed by Viking's obesity portfolio (VK2735, VK3019), which drives essentially all investor attention and valuation. Per the rubric, an early-stage drug with no imminent binary catalyst scores 3-5, and the lack of concentration supports the low end of that range.
VK0214 is not a near-term value driver for VKTX. Investors should focus on Viking's obesity pipeline, particularly the Phase 3 VK2735 program, for material catalysts. VK0214 may become relevant only if it advances to a registrational trial, which has not been announced. The stock's direction is dominated by obesity drug readouts, not this orphan program.
Price Chart
Executive Summary
VK0214 is an oral thyroid hormone receptor beta (THR-β) agonist in development by Viking Therapeutics (VKTX) for X-linked adrenoleukodystrophy (X-ALD), a rare, progressive neurodegenerative disorder. It completed a Phase 1b/2a trial (NCT05284968) in adult male X-ALD patients, showing favorable safety and biomarker signals. However, VK0214 is a minor, early-stage program within Viking's pipeline, the company's overwhelming focus and valuation driver is its obesity/metabolic portfolio (VK2735 GLP-1/GIP agonist and VK3019 amylin agonist). No pivotal trial or regulatory submission is imminent for VK0214, and it receives essentially no investor attention relative to Viking's obesity assets.
How It Works
VK0214 is a small-molecule drug taken by mouth that activates the thyroid hormone receptor beta (THR-β). In X-ALD, a genetic defect (mutated ABCD1 gene) prevents the breakdown of very-long-chain fatty acids, causing them to build up and damage the nervous system. VK0214 works by turning on a related gene (ABCD2) to produce a similar protein that can help break down these toxic fatty acids, potentially slowing or preventing nerve damage.
Trial Status
VK0214 completed a Phase 1b/2a clinical trial (NCT05284968) in adult male patients with X-ALD. The study evaluated safety, tolerability, pharmacokinetics, and biomarkers including very-long-chain fatty acid levels. Topline results reported favorable safety and biomarker improvements. Viking's pipeline currently lists VK0214 in Phase 1b/2a, and no Phase 2b or Phase 3 trial has been announced or initiated as of late 2026. The program appears to be on pause or low priority relative to the company's obesity pipeline.
The Two-Sided Case
Upcoming Catalysts
- Initiation of a Phase 2b or registrational trial for VK0214 in X-ALD
- Potential presentation of updated Phase 1b/2a data at a medical conference
- Orphan Drug Designation already granted, no immediate regulatory decision pending
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Viking Therapeutics, Inc PRESS-RELEASE VKTX ·Originating report